{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T10:12:43Z","timestamp":1769508763339,"version":"3.49.0"},"reference-count":54,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,12,18]],"date-time":"2017-12-18T00:00:00Z","timestamp":1513555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Investigation"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Combined treatment with intravitreal anti\u2010vascular endothelial growth factor (anti\u2010<jats:styled-content style=\"fixed-case\">VEGF<\/jats:styled-content>) and verteporfin photodynamic therapy (<jats:styled-content style=\"fixed-case\">PDT<\/jats:styled-content>) is widely used for patients with polypoidal choroidal vasculopathy (<jats:styled-content style=\"fixed-case\">PCV<\/jats:styled-content>), although clinical evidence regarding the therapeutic efficacy and safety of such treatment remains lacking.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design\/Methods<\/jats:title><jats:p>We performed a meta\u2010analysis of previously reported studies comparing combination treatment, <jats:styled-content style=\"fixed-case\">PDT<\/jats:styled-content> monotherapy, and anti\u2010<jats:styled-content style=\"fixed-case\">VEGF<\/jats:styled-content> monotherapy. Primary outcome measures included changes in best\u2010corrected visual acuity (<jats:styled-content style=\"fixed-case\">BCVA<\/jats:styled-content>) and central retinal thickness (<jats:styled-content style=\"fixed-case\">CRT<\/jats:styled-content>). The proportion of patients with polyp regression was regarded as the secondary outcome measure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty studies (three <jats:styled-content style=\"fixed-case\">RCT<\/jats:styled-content>s and 19 retrospective studies) involving 1,178 patients with <jats:styled-content style=\"fixed-case\">PCV<\/jats:styled-content> were selected. Significant differences in the proportion of patients with polyps were observed between the <jats:styled-content style=\"fixed-case\">PDT<\/jats:styled-content> and anti\u2010<jats:styled-content style=\"fixed-case\">VEGF<\/jats:styled-content> monotherapy groups at 3 and \u22656 months (<jats:italic>P<\/jats:italic> &lt; .00001; and <jats:italic>P<\/jats:italic> = .0001, respectively). Significantly greater reductions in <jats:styled-content style=\"fixed-case\">CRT<\/jats:styled-content> were observed in the anti\u2010<jats:styled-content style=\"fixed-case\">VEGF<\/jats:styled-content> than in the <jats:styled-content style=\"fixed-case\">PDT<\/jats:styled-content> group at the 3\u2010month follow\u2010up (<jats:italic>P<\/jats:italic> = .04). Significantly greater improvements in <jats:styled-content style=\"fixed-case\">BCVA<\/jats:styled-content> were observed in the combined therapy group than in the <jats:styled-content style=\"fixed-case\">PDT<\/jats:styled-content> monotherapy group at 3, 6, 12, and 24 months (<jats:italic>P<\/jats:italic> = .03; <jats:italic>P<\/jats:italic> = .005; <jats:italic>P<\/jats:italic> = .02; and <jats:italic>P<\/jats:italic> &lt; .00001, respectively). Combined treatment also resulted in significantly greater improvements in <jats:styled-content style=\"fixed-case\">BCVA<\/jats:styled-content> than monotherapy with anti\u2010<jats:styled-content style=\"fixed-case\">VEGF<\/jats:styled-content> at 6 and 24 months (<jats:italic>P<\/jats:italic> = .001; <jats:italic>P<\/jats:italic> &lt; .00001, respectively), and significantly greater polyp regression than that observed following anti\u2010<jats:styled-content style=\"fixed-case\">VEGF<\/jats:styled-content> treatment at 3 and \u22656 months (<jats:italic>P<\/jats:italic> &lt; .00001; <jats:italic>P<\/jats:italic> &lt; .0001, respectively).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Combined therapy involving anti\u2010<jats:styled-content style=\"fixed-case\">VEGF<\/jats:styled-content> agents and <jats:styled-content style=\"fixed-case\">PDT<\/jats:styled-content> may be more effective in improving long\u2010term outcomes for patients with <jats:styled-content style=\"fixed-case\">PCV<\/jats:styled-content> than monotherapy.<\/jats:p><\/jats:sec>","DOI":"10.1111\/eci.12840","type":"journal-article","created":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T15:02:39Z","timestamp":1507215759000},"source":"Crossref","is-referenced-by-count":16,"title":["Polypoidal choroidal vasculopathy treatment options: A meta\u2010analysis"],"prefix":"10.1111","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7359-911X","authenticated-orcid":false,"given":"Tianwei","family":"Qian","sequence":"first","affiliation":[{"name":"Department of Ophthalmology Shanghai Key Laboratory of Ocular Fundus Diseases Shanghai General Hospital Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinxin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology Shanghai Key Laboratory of Ocular Fundus Diseases Shanghai General Hospital Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengya","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology Shanghai Key Laboratory of Ocular Fundus Diseases Shanghai General Hospital Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xun","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology Shanghai Key Laboratory of Ocular Fundus Diseases Shanghai General Hospital Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,12,18]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-199001010-00001"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e31826ffe9d"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-199515020-00003"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2013.09.003"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000000499"},{"key":"e_1_2_7_7_1","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3341\/kjo.2015.29.6.404","article-title":"Intravitreal anti\u2010vascular endothelial growth factor for newly diagnosed symptomatic polypoidal choroidal vasculopathy with extrafoveal polyps[J]","volume":"29","author":"Kim JH","year":"2015","journal-title":"Korean J Ophthalmol"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2011.324"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e31816577cb"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.10.012"},{"key":"e_1_2_7_11_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12886-015-0064-5","article-title":"Photodynamic therapy versus anti\u2010vascular endothelial growth factor agents for polypoidal choroidal vasculopathy: a meta\u2010analysis[J]","volume":"15","author":"Yong M","year":"2015","journal-title":"BMC Ophthalmo"},{"key":"e_1_2_7_12_1","first-page":"8","article-title":"Ranibizumab alone or in combination with photodynamic therapy vs photodynamic therapy for polypoidal choroidal vasculopathy: a systematic review and Meta\u2010analysis[J]","volume":"2015","author":"Tang K","journal-title":"Int J ophthalmol"},{"key":"e_1_2_7_13_1","doi-asserted-by":"crossref","first-page":"e110667","DOI":"10.1371\/journal.pone.0110667","article-title":"Combined intravitreal anti\u2010VEGF and photodynamic therapy versus photodynamic monotherapy for polypoidal choroidal vasculopathy: a systematic review and meta\u2010analysis of comparative studies[J]","volume":"9","author":"Wang W","year":"2014","journal-title":"PLoS ONE"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2009.02234.x"},{"key":"e_1_2_7_15_1","unstructured":"HigginsJP GreenS(2011)Cochrane handbook for systematic reviews of interventions. Version 5.1.0[updated March 2011]: The Cochrane Collaboration.http:\/\/handbook.cochrane.org\/"},{"key":"e_1_2_7_16_1","unstructured":"WellsG SheaB O'ConnellD et al.The Newcastle\u2010Ottawa Scale (NOS) for assessing the quality of non\u2010randomised studies in meta\u2010analyses.http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e31824f91e8"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2013.05.024"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2013.04.001"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2007.135103"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.3341\/kjo.2008.22.2.92"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2009.01841.x"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2010.02.008"},{"key":"e_1_2_7_24_1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4103\/0301-4738.64130","article-title":"Comparison of intravitreal bevacizumab to photodynamic therapy for polypoidal choroidal vasculopathy: short\u2010term results[J]","volume":"58","author":"Mitamura Y","year":"2010","journal-title":"Indian J Ophthalmol"},{"key":"e_1_2_7_25_1","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1097\/IAE.0b013e318214d01e","article-title":"Efficacy of combined photodynamic therapy and intravitreal bevacizumab injection versus photodynamic therapy alone in polypoidal choroidal vasculopathy[J]","volume":"31","author":"Kim SJ","year":"2011","journal-title":"Retina"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e31820d3f3f"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2010.10.030"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181f274ec"},{"key":"e_1_2_7_29_1","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1097\/IAE.0b013e31820f4b21","article-title":"Intravitreal ranibizumab for polypoidal choroidal vasculopathy with recurrent or residual exudation[J]","volume":"31","author":"Saito M","year":"2011","journal-title":"Retina"},{"key":"e_1_2_7_30_1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000329466","article-title":"One\u2010year results of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy[J]","volume":"226","author":"Song MH","year":"2011","journal-title":"Ophthalmol"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2012.03.051"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2013.179"},{"key":"e_1_2_7_33_1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000354546","article-title":"Two\u2010year outcome after combination therapy for polypoidal choroidal vasculopathy: comparison with photodynamic monotherapy and anti\u2010vascular endothelial growth factor monotherapy[J]","volume":"231","author":"Kang HM","year":"2013","journal-title":"Ophthalmol"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-013-2323-6"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2013.0044"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000000526"},{"key":"e_1_2_7_37_1","first-page":"1","article-title":"Comparison of initial treatment between 3\u2010monthly intravitreal aflibercept monotherapy and combined photodynamic therapy with single intravitreal aflibercept for polypoidal choroidal vasculopathy[J]","volume":"255","author":"Kikushima W","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.13130"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2009.10.001"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.121.10.1392"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.86.3.321"},{"key":"e_1_2_7_42_1","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1167\/iovs.09-5018","article-title":"Quantification of the therapeutic response of intraretinal, subretinal, and subpigment epithelial compartments in exudative AMD during anti\u2010VEGF therapy[J]","volume":"52","author":"Golbaz I","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_7_43_1","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.ophtha.2003.12.056","article-title":"Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one\u2010year results of a prospective case series[J]","volume":"111","author":"Chan WM","year":"2004","journal-title":"Ophthalmology"},{"key":"e_1_2_7_44_1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ajo.2013.02.006","article-title":"Comparisons of outcomes with different intervals between adjunctive ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy[J]","volume":"156","author":"Sato T","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"e_1_2_7_45_1","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000221837","article-title":"Comparative assessment of photodynamic therapy for typical age\u2010related macular degeneration and polypoidal choroidal vasculopathy: a multicenter study in Hyogo prefecture, Japan[J]","volume":"223","author":"Honda S","year":"2009","journal-title":"Ophthalmol"},{"key":"e_1_2_7_46_1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ajo.2012.08.002","article-title":"Argon laser with and without anti\u2010vascular endothelial growth factor therapy for extrafoveal polypoidal choroidal vasculopathy[J]","volume":"155","author":"Cheung CMG","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.31.1541"},{"key":"e_1_2_7_48_1","doi-asserted-by":"crossref","first-page":"36870","DOI":"10.1038\/srep36870","article-title":"Treatment of polypoidal choroidal vasculopathy by photodynamic therapy, aflibercept and dexamethasone triple therapy[J]","volume":"6","author":"Ho M","year":"2016","journal-title":"Sci Rep"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2015.0150"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2015.03.005"},{"key":"e_1_2_7_51_1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/bjophthalmol-2016-309694","article-title":"Changes of choroidal structure after intravitreal aflibercept therapy for polypoidal choroidal vasculopathy[J]","volume":"101","author":"Daizumoto E","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"e_1_2_7_52_1","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s10384-016-0492-7","article-title":"One\u2010year outcomes of a treat\u2010and\u2010extend regimen of intravitreal aflibercept for polypoidal choroidal vasculopathy[J]","volume":"61","author":"Hosokawa M","year":"2017","journal-title":"Jpn J Ophthalmol"},{"key":"e_1_2_7_53_1","first-page":"1","article-title":"Two\u2010year results of a treat\u2010and\u2010extend regimen with aflibercept for polypoidal choroidal vasculopathy[J]","volume":"2017","author":"Morimoto M","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"e_1_2_7_54_1","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2147\/OPTH.S129164","article-title":"Efficacy of intravitreal aflibercept injections for Japanese patients with polypoidal choroidal vasculopathy[J]","volume":"11","author":"Arakawa A","year":"2017","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"key":"e_1_2_7_55_1","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00417-016-3489-5","article-title":"Efficacy of fixed\u2010dosing aflibercept for treating polypoidal choroidal vasculopathy: 1\u2010year results of the VAULT study[J]","volume":"255","author":"Lee JE","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["European Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Feci.12840","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/eci.12840","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T20:23:54Z","timestamp":1696019034000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/eci.12840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,18]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1111\/eci.12840"],"URL":"https:\/\/doi.org\/10.1111\/eci.12840","archive":["Portico"],"relation":{},"ISSN":["0014-2972","1365-2362"],"issn-type":[{"value":"0014-2972","type":"print"},{"value":"1365-2362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,18]]},"article-number":"e12840"}}